Cinqair.com

IP Server: 45.60.151.76 (See full)
Location: United States (See map)
Registed: 2014-11-14 (9 years, 214 days)
Ping: 20 ms
HostName: 45.60.151.76
DNS Server: ns3.tevapharm.com, ns4.tevapharm.com, ns5.tevapharm.com

Websites Hosted on 45.60.151.76

Domain Search:

Tools Checker

Hosting Provider
Websites on IP

Hostname: 45.60.151.76
Country: United States
Latitude: 37.751
Longitude: -97.822
Email Abuse: No Emails

Analyzing...

https://ewebsiteranking.com

Port Scanner (IP: 45.60.151.76)

› Ftp: 21

› Ssh: 22

› Telnet: 23

› Smtp: 25

› Dns: 53

› Http: 80

› Pop3: 110

› Portmapper, rpcbind: 111

› Microsoft RPC services: 135

› Netbios: 139

› Imap: 143

› Ldap: 389

› Https: 443

› SMB directly over IP: 445

› Msa-outlook: 587

› IIS, NFS, or listener RFS remote_file_sharing: 1025

› Lotus notes: 1352

› Sql server: 1433

› Point-to-point tunnelling protocol: 1723

› My sql: 3306

› Remote desktop: 3389

› Session Initiation Protocol (SIP): 5060

› Virtual Network Computer display: 5900

› X Window server: 6001

› Webcache: 8080

Top Keywords Suggestions

› Cinqair

› Cinqair asthma

› Cinqair dosing

› Cinqair package insert

› Cinqair order form

› Cinqair reslizumab

› Cinqair infusion

› Cinqair cost

› Cinqair hcp

Top 10 related websites

CINQAIRhttps://www.cinqair.com/about-cinqair

WEBCINQAIR is a treatment for severe, uncontrolled eosinophilic asthma. CINQAIR is an add-on prescription medication for people 18 years of age and older. Don’t forget to …

DA: 15 PA: 15 MOZ Rank: 30

Go URL

CINQAIR HCPhttps://www.cinqairhcp.com/about

WEBCINQAIR is an interleukin-5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older, …

DA: 18 PA: 7 MOZ Rank: 26

Go URL

CINQAIRhttps://www.cinqair.com/patient-resources

WEBFind helpful patient resources, including tools and information to support you on your journey with CINQAIR.

DA: 15 PA: 19 MOZ Rank: 36

Go URL

Food and Drug Administration (.gov)https://www.fda.gov/news-events/press

WEBThe U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients …

DA: 11 PA: 50 MOZ Rank: 87

Go URL

CINQAIR HCPhttps://www.cinqairhcp.com

WEBINDICATIONS AND USAGE. CINQAIR is an interleukin-5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with severe …

DA: 18 PA: 18 MOZ Rank: 23

Go URL

Drugs.comhttps://www.drugs.com/cinqair.html

WEBMar 25, 2024 · Cinqair (reslizumab) is a monoclonal antibody that affects the actions of the body's immune system. Reslizumab works by reducing levels of a certain type of white …

DA: 13 PA: 13 MOZ Rank: 31

Go URL

Teva Pharmaceutical Industries Ltd.https://www.tevapharm.com/news-and-media/latest

WEBMar 23, 2016 · Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved CINQAIR® …

DA: 17 PA: 50 MOZ Rank: 44

Go URL

fda.govhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdf

WEBReslizumab is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. Reslizumab has a molecular weight of approximately 147 kDa. CINQAIR …

DA: 22 PA: 41 MOZ Rank: 70

Go URL

Recently Analyzed

› Myhome.us (4 seconds ago) / US

› Skicrescendo.com (4 seconds ago) / US

› Mnwest.edu (8 seconds ago) /

› Wholesalerbaba.com (35 seconds ago) / US

› 2pour.com (40 seconds ago) / UA

› Stewarthome.com (52 seconds ago) / US